A Cost-Effectiveness Analysis of Guanfacine Extended-Release Treatment in Pediatric Attention-Deficit/Hyperactivity Disorder

Cost Effectiveness ◽

Attention Deficit ◽

Extended Release ◽

Cost Effectiveness Analysis ◽

Hyperactivity Disorder ◽

Effectiveness Analysis

A cost-effectiveness analysis of lisdexamfetamine dimesylate in the treatment of adults with attention-deficit/hyperactivity disorder in the UK

The European Journal of Health Economics ◽

10.1007/s10198-016-0864-4 ◽

2017 ◽

Vol 19 (1) ◽

pp. 21-35 ◽

Cited By ~ 5

Author(s):

Evelina A. Zimovetz ◽

Alain Joseph ◽

Rajeev Ayyagari ◽

Josephine A. Mauskopf

Keyword(s):

Cost Effectiveness ◽

Attention Deficit ◽

Cost Effectiveness Analysis ◽

Lisdexamfetamine Dimesylate ◽

Hyperactivity Disorder ◽

Effectiveness Analysis ◽

The Uk

PIH23 Cost-Effectiveness of Guanfacine Extended Release as an Adjunctive Therapy to a Psychostimulant Compared to Psychostimulant Monotherapy for the Treatment of Attention Deficit/Hyperactivity Disorder in Children and Adolescents

Value in Health ◽

10.1016/j.jval.2011.08.927 ◽

2011 ◽

Vol 14 (7) ◽

pp. A401-A402 ◽

Cited By ~ 1

Author(s):

V. Sikirica ◽

M. Erder ◽

J. Xie ◽

D. Macaulay ◽

M. Diener ◽

...

Keyword(s):

Cost Effectiveness ◽

Attention Deficit ◽

Adjunctive Therapy ◽

Extended Release ◽

Cost-effectiveness of guanfacine extended-release as an adjunctive therapy to a long-acting stimulant versus long-acting stimulant monotherapy for the treatment of attention-deficit/hyperactivity disorder in Canada

Value in Health ◽

10.1016/j.jval.2014.03.1251 ◽

2014 ◽

Vol 17 (3) ◽

pp. A214 ◽

Cited By ~ 1

Author(s):

J. Lachaine ◽

V. Sikirica ◽

K. Mathurin

Keyword(s):

Cost Effectiveness ◽

Attention Deficit ◽

Adjunctive Therapy ◽

Extended Release ◽

Hyperactivity Disorder ◽

Long Acting

Cost-effectiveness of guanfacine extended-release versus atomoxetine for the treatment of children and adolescents with attention-deficit/hyperactivity disorder in Canada

Value in Health ◽

10.1016/j.jval.2014.03.1250 ◽

2014 ◽

Vol 17 (3) ◽

pp. A213-A214

Author(s):

J. Lachaine ◽

V. Sikirica ◽

K. Mathurin

Keyword(s):

Cost Effectiveness ◽

Attention Deficit ◽

Extended Release ◽

Cost Effectiveness of Guanfacine Extended Release as an Adjunctive Therapy to a Stimulant Compared with Stimulant Monotherapy for the Treatment of Attention-Deficit Hyperactivity Disorder in Children and Adolescents

PharmacoEconomics ◽

10.2165/11632920-000000000-00000 ◽

2012 ◽

Vol 30 (8) ◽

pp. e1-e15 ◽

Cited By ~ 14

Author(s):

Vanja Sikirica ◽

M. Haim Erder ◽

Jipan Xie ◽

Dendy Macaulay ◽

Melissa Diener ◽

...

Keyword(s):

Cost Effectiveness ◽

Attention Deficit ◽

Adjunctive Therapy ◽

Extended Release ◽

Cost Effectiveness of Guanfacine Extended-Release Versus Atomoxetine for the Treatment of Attention-Deficit/Hyperactivity Disorder: Application of a Matching-Adjusted Indirect Comparison

Applied Health Economics and Health Policy ◽

10.1007/s40258-013-0024-2 ◽

2013 ◽

Vol 11 (3) ◽

pp. 305-305

Author(s):

Carlos I. Alatorre ◽

Virginia Haynes ◽

Douglas Faries ◽

Himanshu Upadhyaya ◽

Douglas Kelsey

Keyword(s):

Cost Effectiveness ◽

Attention Deficit ◽

Extended Release ◽

Indirect Comparison ◽

Hyperactivity Disorder ◽

Adjusted Indirect Comparison

Cost Effectiveness of Guanfacine Extended-Release versus Atomoxetine for the Treatment of Attention-Deficit/Hyperactivity Disorder

Applied Health Economics and Health Policy ◽

10.1007/bf03261873 ◽

2012 ◽

Vol 10 (6) ◽

pp. 381-395 ◽

Cited By ~ 11

Author(s):

M. Haim Erder ◽

Jipan Xie ◽

James E. Signorovitch ◽

Kristina S. Chen ◽

Paul Hodgkins ◽

...

Keyword(s):

Cost Effectiveness ◽

Attention Deficit ◽

Extended Release ◽

Erratum to: Cost Effectiveness of Guanfacine Extended-Release versus Atomoxetine for the Treatment of Attention-Deficit/Hyperactivity Disorder

Applied Health Economics and Health Policy ◽

10.1007/s40258-013-0015-3 ◽

2013 ◽

Vol 11 (3) ◽

pp. 309-309

Author(s):

M. Haim Erder ◽

Jipan Xie ◽

James E. Signorovitch ◽

Kristina S. Chen ◽

Paul Hodgkins ◽

...

Keyword(s):

Cost Effectiveness ◽

Attention Deficit ◽

Extended Release ◽

PMH37 THE COST-EFFECTIVENESS OF GUANFACINE EXTENDED RELEASE (GXR) VERSUS ATOMOXETINE (ATX) FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD) IN CHILDREN AND ADOLESCENTS

Value in Health ◽

10.1016/j.jval.2011.02.1061 ◽

2011 ◽

Vol 14 (3) ◽

pp. A192 ◽

Cited By ~ 1

Author(s):

M. Erder ◽

K. Chen ◽

E.Q. Wu ◽

P. Hodgkins ◽

V. Sikirica

Keyword(s):

Cost Effectiveness ◽

Attention Deficit ◽

Extended Release ◽

Hyperactivity Disorder ◽

The Cost

Cost-Effectiveness of Extended-Release Methylphenidate in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder Sub-Optimally Treated with Immediate Release Methylphenidate

PLoS ONE ◽

10.1371/journal.pone.0127237 ◽

2015 ◽

Vol 10 (5) ◽

pp. e0127237 ◽

Cited By ~ 6

Author(s):

Jurjen van der Schans ◽

Nikos Kotsopoulos ◽

Pieter J. Hoekstra ◽

Eelko Hak ◽

Maarten J. Postma

Keyword(s):

Cost Effectiveness ◽

Attention Deficit ◽

Extended Release ◽

Immediate Release ◽